Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma
about
sameAs
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancermiR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressorProtein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancerMicroRNAs in cancer: from developmental genes in worms to their clinical application in patientsA 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinomaEpidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma.NF-κB and stat3 transcription factor signatures differentiate HPV-positive and HPV-negative head and neck squamous cell carcinoma.Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!Epigenetic regulation of miR-212 expression in lung cancer.AXL mediates resistance to cetuximab therapyA new analysis approach of epidermal growth factor receptor pathway activation patterns provides insights into cetuximab resistance mechanisms in head and neck cancerHistone demethylase retinoblastoma binding protein 2 is overexpressed in hepatocellular carcinoma and negatively regulated by hsa-miR-212.Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers.Transcriptional changes associated with resistance to inhibitors of epidermal growth factor receptor revealed using metaanalysis.MicroRNA-212 negatively regulates starvation induced autophagy in prostate cancer cells by inhibiting SIRT1 and is a modulator of angiogenesis and cellular senescenceDown-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancermiR-212/132 expression and functions: within and beyond the neuronal compartment.MicroRNA-212 inhibits hepatocellular carcinoma cell proliferation and induces apoptosis by targeting FOXA1.CoGAPS matrix factorization algorithm identifies transcriptional changes in AP-2alpha target genes in feedback from therapeutic inhibition of the EGFR network.Targeting autocrine HB-EGF signaling with specific ADAM12 inhibition using recombinant ADAM12 prodomain.Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance.MicroRNA-212 functions as an epigenetic-silenced tumor suppressor involving in tumor metastasis and invasion of gastric cancer through down-regulating PXN expression.Alterations of microRNA expression patterns in human cervical carcinoma cells (Ca Ski) toward 1'S-1'-acetoxychavicol acetate and cisplatin.Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximabHeparin-binding EGF-like growth factor and miR-1192 exert opposite effect on Runx2-induced osteogenic differentiation.Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop.Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines.Current trends in miRNAs and their relationship with oral squamous cell carcinoma.MicroRNAs in pancreatic cancer metabolism.microRNA regulation of cell viability and drug sensitivity in lung cancer.While at Rome miRNA and TRAIL do whatever BCR-ABL commands to do.Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistanceUpdate of molecular pathobiology in oral cancer: a review.Emerging EGFR antagonists for breast cancer.Emerging biomarkers in head and neck cancer in the era of genomics.Prognostic microRNAs in cancer tissue from patients operated for pancreatic cancer--five microRNAs in a prognostic index.Pharmacologic treatment options for advanced epithelial skin cancer.A novel functional splice variant of AKT3 defined by analysis of alternative splice expression in HPV-positive oropharyngeal cancers.
P2860
Q24604601-1138C441-DCBC-4B62-921D-EE90F0758F17Q24628906-B9CC1BB2-C23B-47B6-982C-FC17B744B3ACQ26852215-09B5DBCB-F785-4EEA-AC27-D7C77B7F6BD9Q26865275-F509AE7F-9C38-4E92-84EF-E7D0287E3070Q27853046-B5003E95-F866-4610-990F-1360175F525FQ27853131-43D3765E-3097-418F-B5F8-C3A6EFE1E121Q27853173-AB3EDF91-F532-4D0F-BDCF-C4DBA17BBFD1Q30300214-F9524356-E386-4545-9BE6-CCBC87D6245FQ33356339-6FFF3B5A-E5D9-4DCB-9792-6FBE410373B5Q34081763-40B895B1-2E41-4591-A0B6-B153D7669F24Q34204829-AE907EB3-EDB4-4FFF-A59B-8835F4DADDA2Q34252978-95B057C8-65B2-4475-AB6C-796305947DCFQ34903864-E8F333D3-EC57-4F13-8E93-088103F2CE6AQ35001415-46B120E2-12B8-46BA-992E-812D17A44215Q35571452-B51A8B10-AF50-42E1-9E93-8BC2FE271D0FQ35604127-5847D60A-3171-4ECE-B58D-C46794711A5CQ35800562-18EDF59D-6B8B-4924-A602-AFB80A318B1FQ35998435-735C0201-C48E-416D-A5ED-7988281D1FECQ36008128-9E7DF84F-8239-46AA-B85D-10C5F98739E3Q36015134-D6C08E04-2780-434A-BA7A-17D0FA5D0825Q36138884-75C742B9-18C0-4BD4-940A-03AEC7DD5F1FQ36174467-977CADE8-C5AC-47CC-A290-3CAACE76D7CCQ36185012-DE14347B-03E3-47AD-957A-31BD39ADB66DQ36309371-8FAAD202-FF68-4C88-B6F1-350D356BAA65Q37019591-A4626A9A-A916-4873-BB5E-A600C5F4DB71Q37285565-374604CD-A88B-4358-8D60-3A8849F2D067Q37299648-64C55987-BB82-4A21-9E8E-15852AA80EE2Q37494943-3BEBC93D-933E-4044-A879-CDDC02280301Q37703226-82A83EB5-6FEA-4B6E-A94A-162E2F2DE87FQ37970449-C6291E00-2C8F-4336-A7E8-3649055F1413Q38003048-E1762936-E694-4DB3-B938-074517B9DDECQ38021509-B7134723-B811-4DDC-A277-5D2F9A0D8AC3Q38066406-A8615638-966C-4AD5-B334-BCCC97EEDBD4Q38118934-0B9BFF3A-D32A-4646-9ABA-A88AE80EB3DEQ38198988-CBAD6A5F-E738-4F02-9A8D-0543AD00CD49Q38211951-25F269D7-7313-4448-8C37-B5A0E505F48AQ38268896-8DC3A8E9-AF04-4C49-8359-681F14A656DBQ38431137-D7336DDE-504E-42DD-A1A1-44C5AAC8532DQ38509273-4AC8629C-641E-4EC8-9DE0-71EA031EF1A1Q38667225-DCBF7BF0-BAFF-44BF-8CEF-E7786D26DB95
P2860
Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Regulation of heparin-binding ...... d neck squamous cell carcinoma
@ast
Regulation of heparin-binding ...... d neck squamous cell carcinoma
@en
Regulation of heparin-binding ...... d neck squamous cell carcinoma
@nl
type
label
Regulation of heparin-binding ...... d neck squamous cell carcinoma
@ast
Regulation of heparin-binding ...... d neck squamous cell carcinoma
@en
Regulation of heparin-binding ...... d neck squamous cell carcinoma
@nl
prefLabel
Regulation of heparin-binding ...... d neck squamous cell carcinoma
@ast
Regulation of heparin-binding ...... d neck squamous cell carcinoma
@en
Regulation of heparin-binding ...... d neck squamous cell carcinoma
@nl
P2093
P2860
P1433
P1476
Regulation of heparin-binding ...... d neck squamous cell carcinoma
@en
P2093
Ashley Counsell
Barbara Murphy
Carey Burton Wood
Christine H Chung
Deric L Wheeler
Haixia Cheng
Hiromitsu Hatakeyama
Jill Gilbert
Pamela Wirth
Paul M Harari
P2860
P304
P356
10.1371/JOURNAL.PONE.0012702
P407
P577
2010-09-13T00:00:00Z